CDC Recommends First Vaccine to Protect Infants from RSV
Abrysvo reportedly reduces risk of condition in baby by 57% in the first six months after birth.
The CDC has endorsed the first respiratory syncytial virus (RSV) vaccine for pregnant people to protect their newborn from severe RSV illness. Developed by Pfizer, Abrysvo has been shown to reduce the risk of RSV hospitalization for babies by 57% in the first six months after birth. According to a company press release, the CDC recommends seasonal administration of one dose of RSV vaccine for pregnant people during weeks 32 through 36 of pregnancy, citing better ability to protect babies after birth.
“This is another new tool we can use this fall and winter to help protect lives,” said CDC director Mandy Cohen, MD, MPH. “I encourage parents to talk to their doctors about how to protect their little ones against serious RSV illness, using either a vaccine given during pregnancy, or an RSV immunization given to your baby after birth.”
Reference: CDC recommends new vaccine to help protect babies against severe respiratory syncytial virus (RSV) illness after birth. CDC. September 22, 2023. Accessed September 25, 2023. https://www.cdc.gov/media/releases/2023/p0922-RSV-maternal-vaccine.html
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
